1-20 of 23
Anthony Elias
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway

Open Access
Michael P. Ludwig, Matthew D. Galbraith, Neetha Paul Eduthan, Amanda A. Hill, Michael R. Clay, Cristiam Moreno Tellez, Breelyn A. Wilky, Anthony Elias, Joaquin M. Espinosa, Kelly D. Sullivan
Journal: Cancer Research
Cancer Res (2023) 83 (15): 2543–2556.
https://doi.org/10.1158/0008-5472.CAN-22-3173
Published: 01 August 2023
View articletitled, Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
Open the PDF for Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway in another window
Includes: Supplementary data
Journal Articles

Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Free
Claudine Isaacs, Rita Nanda, Jo Chien, Meghna S. Trivedi, Erica Stringer-Reasor, Christos Vaklavas, Judy C. Boughey, Amy Sanford, Anne Wallace, Amy S. Clark, Alexandra Thomas, Kathy S. Albain, Laura C. Kennedy, Tara B. Sanft, Kevin Kalinsky, Hyo S. Han, Nicole Williams, Mili Arora, Anthony Elias, Carla Falkson, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS5-03.
https://doi.org/10.1158/1538-7445.SABCS22-GS5-03
Published: 01 March 2023
View articletitled, Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract CT120: Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer

Free
Anna R. Schreiber, Jodi Kagihara, Andrew Nicklawsky, Dexiang Gao, Anosheh Afghahi, Anthony Elias, Peter Kabos, Elena Shagisultanova, Todd Pitts, Julie Lang, Sana Karam, Virginia Borges, Christine Fisher, Jennifer R. Diamond
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT120.
https://doi.org/10.1158/1538-7445.AM2022-CT120
Published: 15 June 2022
View articletitled, Abstract CT120: Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer
Journal Articles

Abstract 1639: Human immune system mouse model of ER+ metastatic breast cancer

Free
Ayodeji Olukoya, Shaymaa Bahnassy, Nicole S. Spoelstra, Lu Jin, Suman Ranjit, Anthony Elias, Jennifer K. Richer, Rebecca B. Riggins
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1639.
https://doi.org/10.1158/1538-7445.AM2022-1639
Published: 15 June 2022
View articletitled, Abstract 1639: Human immune system mouse model of ER+ metastatic breast cancer
Journal Articles

Abstract P1-17-01: Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide

Free
Jennifer Richer, Nicole Spoelstra, Alyse Winchester, Julia Wulfkuhlue, Rosa Gallagher, Sharon Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadded, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony Elias
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-17-01.
https://doi.org/10.1158/1538-7445.SABCS21-P1-17-01
Published: 15 February 2022
View articletitled, Abstract P1-17-01: Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide
Journal Articles

Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

Free
Beverly Kyalwazi, Christina Yau, Olufunmilayo Olopade, A. Jo Chien, Anne Wallace, Andres Forero-Torres, Lajos Pusztai, Erin Ellis, Kathy Albain, Anne Blaes, Barbara Haley, Judy Boughey, Anthony Elias, Amy Clark, Claudine Isaacs, Rita Nanda, Hyo Han, Rachel Yung, Debu Tripathy, Kristen Edmiston, Rebecca Viscusi, Donald Northfelt, Qamar Khan, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian Hirst, Nola Hylton, Michelle Melisko, Jane Perlmutter, Hope Rugo, Fraser Symmans, Laura van ‘t Veer, Donald Berry, Laura Esserman
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-02.
https://doi.org/10.1158/1538-7445.SABCS21-GS4-02
Published: 15 February 2022
View articletitled, Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Journal Articles

Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

Free
Soliman Hatem, Jeffrey Hargis, Anthony Elias, Arielle Lee, Rachel Swart, Shaker Dahkil, Alexandra Drakaki, Vu Phan, Frederic Kass, Melody Cobleigh, Sanil Babu, Katherine Tkaczuk, Brenda O'Connell, Jennifer Roberts, Nora Zizlsperger, Erika Hamilton
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-16-02.
https://doi.org/10.1158/1538-7445.SABCS21-P5-16-02
Published: 15 February 2022
View articletitled, Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)
Journal Articles

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Free
Heather Beckwith, Richard Schwab, Christina Yau, Erica Stringer-Reasor, Shi Wei, A. Jo Chien, Kathy S Albain, Kevin Kalinsky, Anne Wallace, Anthony Elias, Douglas Yee, Amy S Clark, Judy C Boughey, Heather Han, Rita Nanda, Claudine Isaacs, Zahi Mitri, Julie E Lang, Alexandra Thomas, Tara Sanft, Angela DeMichele, Jane Perlmutter, Hope S Rugo, Nola M Hylton, W. Fraser Symmans, Michelle E Melisko, Laura J van't Veer, I-SPY 2 Consortium, Amy Wilson, Smita M Asare, Ashish Sanil, Donald A Berry, Laura J Esserman
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD1-10.
https://doi.org/10.1158/1538-7445.SABCS20-PD1-10
Published: 15 February 2021
View articletitled, Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Journal Articles

Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer

Free
Michelle M. Williams, Nicole S. Spoelstra, Spencer Arnesen, Kathleen I. O'Neill, Jessica L. Christenson, Jordan Reese, Kathleen C. Torkko, Andrew Goodspeed, Emmanuel Rosas, Toru Hanamura, Sharon B. Sams, Zheqi Li, Steffi Oesterreich, Rebecca B. Riggins, Britta M. Jacobsen, Anthony Elias, Jason Gertz, Jennifer K. Richer
Journal: Cancer Research
Cancer Res (2021) 81 (3): 732–746.
https://doi.org/10.1158/0008-5472.CAN-20-1200
Published: 01 February 2021
View articletitled, Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
Open the PDF for Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Free
Lajos Pusztai, Hyo S. Han, Christina Yau, Denise Wolf, Anne M. Wallace, Rebecca Shatsky, Teresa Helsten, Judy C. Boughey, Tufia Haddad, Erica Stringer-Reasor, Carla Falkson, A. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. van't Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT011.
https://doi.org/10.1158/1538-7445.AM2020-CT011
Published: 15 August 2020
View articletitled, Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Journal Articles

Abstract P6-04-13: Preclinical and clinical analyses of estrogen receptor alpha mutant metastatic breast cancer

Free
Jennifer K Richer, Michelle M Williams, Nicole S Spoelstra, Spencer Arnesen, Jessica L Christenson, Kathleen O’Neill, Jordan M Reese, Zannel D Blanchard, Toru Hanamura, Britta M Jacobsen, Jason Gertz, Anthony Elias
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-04-13.
https://doi.org/10.1158/1538-7445.SABCS19-P6-04-13
Published: 15 February 2020
View articletitled, Abstract P6-04-13: Preclinical and clinical analyses of estrogen receptor alpha mutant metastatic breast cancer
Journal Articles

Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer

Free
Valerie N. Barton, Jessica L. Christenson, Michael A. Gordon, Lisa I. Greene, Thomas J. Rogers, Kiel Butterfield, Beatrice Babbs, Nicole S. Spoelstra, Nicholas C. D'Amato, Anthony Elias, Jennifer K. Richer
Journal: Cancer Research
Cancer Res (2017) 77 (13): 3455–3466.
https://doi.org/10.1158/0008-5472.CAN-16-3240
Published: 02 July 2017
View articletitled, Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer
Open the PDF for Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Free
Meredith Buxton, Angela M. DeMichele, Stephen Chia, Laura van't Veer, Jo Chien, Anne Wallace, Henry Kaplan, Julie Lang, Douglas Yee, Claudine Isaacs, Stacy Moulder, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Susan Minton, Andres Forero, Rita Nanda, Anthony Elias, Larissa Korde, Rebecca Viscuzi, Hope Rugo, Richard Schwab, Fraser Symmans, Melissa Paoloni, Nola Hylton, Michael Hogarth, Julia Lyandres, Jane Perlmutter, Ashish Sanil, Christina Yau, Laura Esserman, Don Berry, I-SPY 2 TRIAL Investigators
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT106.
https://doi.org/10.1158/1538-7445.AM2016-CT106
Published: 15 July 2016
View articletitled, Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Free
Angela M. DeMichele, Stacy Moulder, Meredith Buxton, Douglas Yee, Anne Wallace, Jo Chien, Claudine Isaacs, Kathy Albain, Judy Boughey, Kathleen Kemmer, Barbara Haley, Julie Lang, Henry Kaplan, Susan Minton, Andres Forero, Anthony Elias, Rita Nanda, Larissa Korde, Richard Schwab, Michelle Melisko, Ashish Sanil, Michael Hogarth, Nola Hylton, Melissa Paoloni, Fraser Symmans, Jane Perlmutter, Julia Lyandres, Christina Yau, Don Berry, Laura Esserman, I-SPY 2 TRIAL Investigators
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT042.
https://doi.org/10.1158/1538-7445.AM2016-CT042
Published: 15 July 2016
View articletitled, Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract P6-03-07: Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR

Free
Michael A Gordon, Nicholas D'Amato, Haihua Gu, Darren Wong, Anthony Elias, Jennifer K Richer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P6-03-07.
https://doi.org/10.1158/1538-7445.SABCS14-P6-03-07
Published: 01 May 2015
View articletitled, Abstract P6-03-07: Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR
Journal Articles

Abstract P3-04-06: Inhibiting androgen receptor nuclear localization decreases estrogen receptor (ER) activity and tumor growth in ER+ breast cancer

Free
Nicholas C D'Amato, Britta M Jacobsen, Dawn R Cochrane, Nicole S Spoelstra, Beatrice L Babbs, Anthony Elias, Jennifer K Richer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-04-06.
https://doi.org/10.1158/1538-7445.SABCS14-P3-04-06
Published: 01 May 2015
View articletitled, Abstract P3-04-06: Inhibiting androgen receptor nuclear localization decreases estrogen receptor (ER) activity and tumor growth in ER+ breast cancer
Journal Articles

Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

Free
Denise M Wolf, Christina Yau, Ashish Sanil, Jo Chien, Anne Wallace, Angela DeMichele, Hank Kaplan, Doug Yee, Claudine Isaacs, Kathy Albain, Rebecca Viscuzi, Judy Boughey, Stacey Moulder, Steven Chui, Qamar Khan, Toncred Styblo, Kirsten Edmiston, Donald Northfelt, Anthony Elias, Barbara Haley, Debu Tripathy, Lamorna Brown-Swigart, Susan Flynn, Gillian Hirst, Meredith Buxton, Nola Hylton, Melissa Paoloni, Fraser Symmans, Laura Esserman, Don Berry, Hope Rugo, Olufunmilayo I. Olopade, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-25.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-25
Published: 01 May 2015
View articletitled, Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Journal Articles

Abstract P4-04-06: CD146 positive and negative stroma direct breast tumor estrogen receptor levels, therapeutic response and metastatic potential

Free
Heather M Brechbuhl, Jessica J Finlay-Schultz, Tomomi M Yamamoto, Austin E Gillen, Anthony Elias, Carol A Sartorius, Peter Kabos
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-04-06.
https://doi.org/10.1158/1538-7445.SABCS14-P4-04-06
Published: 01 May 2015
View articletitled, Abstract P4-04-06: CD146 positive and negative stroma direct breast tumor estrogen receptor levels, therapeutic response and metastatic potential
Journal Articles

Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

Free
Christina Yau, Denise M Wolf, Ashish Sanil, Jo Chien, Anne Wallace, Judy Boughey, Doug Yee, Debu Tripathy, Angela DeMichele, Rita Nanda, Steven Chiu, Claudine Isaacs, Kathy Albain, Hank Kaplan, Stacey Moulder, Rebecca Viscusi, Donald Northfelt, Kirsten Edmiston, Anthony Elias, Toncred Styblo, Barbara Haley, Lamorna Brown-Swigart, Susan Flynn, Gillian L Hirst, Meredith Buxton, Nola Hylton, Melissa Paoloni, W Fraser Symmans, Laura Esserman, Don Berry, Minetta C Liu, John W Park, Laura van 't Veer
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-29.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-29
Published: 01 May 2015
View articletitled, Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Journal Articles

Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

Free
John W. Park, Minetta C. Liu, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Fraser Symmans, Meredith B. Buxton, A. Jo Chien, Amy Wallace, Michelle Melisko, Richard Schwab, Judy Boughey, Debashish Tripathy, Hank Kaplan, Rita Nanda, Stephen Chui, Kathy S. Albain, Stacy Moulder, Anthony Elias, Julie E. Lang, Kirsten Edminston, Donald Northfelt, David Euhus, Qamar Khan, Julia Lyandres, Sarah E. Davis, Christina Yau, Ashish Sanil, Laura J. Esserman, Donald A. Berry
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT227.
https://doi.org/10.1158/1538-7445.AM2014-CT227
Published: 01 October 2014
View articletitled, Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL